ArticleCase reports in urology2026
Solitary Testicular Metastasis From Ductal Prostate Cancer 5 Years After Radical Prostatectomy: A Case Report.
Article in Case reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Solitary Testicular Metastasis From Ductal Prostate Cancer 5 Years After Radical Prostatectomy: A Case Report.Case reports in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testicular metastases from prostate carcinoma are exceedingly uncommon, particularly from the ductal histological subtype, which is associated with aggressive clinical behavior and a propensity for atypical metastatic dissemination. We report the case of a 73-year-old male with a history of prostate ductal adenocarcinoma (PDA) treated in 2018 with robot-assisted radical prostatectomy (RARP) and extended pelvic lymphadenectomy. Pathological staging was pT2c R0 N0 (0/53 nodes), and postoperative PSA was undetectable. The patient remained free of recurrence for 5 years. In March 2023, a biochemical recurrence prompted repeated thoracoabdominal computed tomography (CT) and pelvic magnetic resonance imaging (MRI) scans; neither study included dedicated scrotal imaging, and both were negative for recurrence. By March 2024, serum PSA had increased to 5.6 ng/mL, coinciding with the onset of progressive, painless enlargement of the left testicle. Scrotal ultrasonography revealed a solid mass replacing the left testicular parenchyma. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) and choline PET/CT showed a hypermetabolic lesion confined to the left testis, with no evidence of extratesticular disease. The patient underwent left inguinal orchiectomy. Histopathological examination revealed metastatic adenocarcinoma with papillary architecture, morphologically consistent with ductal prostate origin. PSA levels declined rapidly postoperatively, reaching 0.07 ng/mL within 40 days. At 13-month follow-up, the patient remained clinically and biochemically free of disease without further treatment. This case represents one of the few documented instances of solitary testicular metastasis from PDA. It underscores the importance of continued PSA monitoring and highlights that isolated testicular involvement, whereas rare, may confer a more favorable prognosis than typically expected in metastatic PDA. In selected cases, orchiectomy may serve both diagnostic and therapeutic roles, supporting a conservative postoperative approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.